Breast Breast Cancer Guide Tamoxifen for Breast Cancer Treatment, Prevention Medically Reviewed by Dany P
Last updated on Jul 27, 2023
For women with early-stage oestrogen receptor (ER)-positive breast cancer, adjuvant tamoxifen reduces 15-year breast cancer mortality by a third
The advantage of aromatase inhibitor-based treatment over tamoxifen alone for postmenopausal, ER-positive cancers extended across all commonly tested tumour
Interestingly, 5–10% of the ER-negative breast cancers have also shown sensitivity to tamoxifen treatment
The following foods (or major components) have been found to reduce the effectiveness of tamoxifen: Soy foods, especially soybeans, soy protein isolate, soybean paste
Several therapeutic options are available for women with early stage HR-positive breast cancer who are pre-menopausal at diagnosis (Figure 1)
In the study described below, researchers pooled data from 20 trials comparing about 5 years of adjuvant tamoxifen
For example, depending on the Oncotype risk score, the risk of recurrence after 10 years of tamoxifen can range from about 7% (if low risk, as measured by Oncotype) up to about 30% (if high risk by Oncotype)
Hormone therapy may be given before breast surgery
In general, tamoxifen reduces the risk of developing breast cancer by at
Tamoxifen is a prescription medication used to treat breast cancer and lower the chance of developing breast cancer
While adjuvant treatment with the selective-estrogen receptor modulator (SERM) tamoxifen has been the standard of care for pre-menopausal patients with hormone receptor (HR) positive breast cancer Tamoxifen (ta-MOX-i-fen) is a drug that is used to treat many types of cancers
The use of risk-lowering drugs may be called chemoprevention, although no chemotherapy is involved
Ductal carcinoma in situ (DCIS) means the cells that line the milk ducts of the breast have become cancer, but they have not spread into surrounding breast tissue
Although both aromatase inhibitors and tamoxifen can cause menopausal symptoms, such as hot flashes, many of their side effects differ
Results A total of 6,953 women joined this trial
Plasma tamoxifen metabolites (endoxifen, 4-OH tamoxifen, and N-desmethyl-tamoxifen) were reduced in women receiving DIM versus placebo (P